Millennium Management’s Acrivon Therapeutics ACRV Stock Holding History

Millennium Management’s Portfolio ACRV Stock Details ACRV Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	–	Sell	-121,524	Closed	-$293K	–	5636
2025 Q4	$293K	Sell	121,524 -63,710	-34%	-$138K	﹤0.01%	5277
2025 Q3	$335K	Sell	185,234 -111,005	-37%	-$156K	﹤0.01%	5291
2025 Q2	$353K	Buy	+296,239	New	+$407K	﹤0.01%	5108
2024 Q4	–	Sell	-39,750	Closed	-$278K	–	5896
2024 Q3	$278K	Buy	+39,750	New	+$313K	﹤0.01%	5244
2024 Q2	–	Sell	-95,497	Closed	-$683K	–	5812
2024 Q1	$683K	Buy	+95,497	New	+$443K	﹤0.01%	4597
2023 Q1	–	Sell	-19,639	Closed	-$226K	–	6296
2022 Q4	$226K	Buy	+19,639	New	+$249K	﹤0.01%	5257

Other funds holding ACRV

RCM

RA Capital Management Boston, Massachusetts $9.44B AUM 157.3% 1-Year Est. Return

SCV

Sands Capital Ventures Arlington, Virginia $421M AUM 26.25% 1-Year Est. Return

Wellington Management Group Boston, Massachusetts $535B AUM 26.23% 1-Year Est. Return

Acadian Asset Management Boston, Massachusetts $70.5B AUM 36% 1-Year Est. Return

Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

Marshall Wace London, United Kingdom $100B AUM 35.1% 1-Year Est. Return

Two Sigma Investments New York $124B AUM 33.93% 1-Year Est. Return

Jane Street New York $777B AUM 61.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Millennium Management's ACRV Position: Q1 2026 in Review

Millennium Management sold out of Acrivon Therapeutics (ACRV) in Q1 2026, closing a stake of 121,524 shares — an estimated $293K sold.

Millennium Management first reported a position in ACRV in Q4 2022 and held it in 6 quarters. The position peaked at $683K in Q1 2024. 44 funds tracked by Wall St. Rank hold ACRV as of Q1 2026.

Millennium Management reported no remaining Acrivon Therapeutics position as of Q1 2026 after selling out during the quarter.
Millennium Management sold 121,524 Acrivon Therapeutics shares in Q1 2026, an estimated $293K.
Millennium Management first reported a position in Acrivon Therapeutics in Q4 2022 and held it in 6 quarters.
Millennium Management's Acrivon Therapeutics position peaked at $683K in Q1 2024.
44 funds tracked by Wall St. Rank held Acrivon Therapeutics as of Q1 2026.

Based on Millennium Management's 13F filing for Q1 2026, filed 15 May 2026.